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ABSTRACT: A series of multinuclear heterometallic Cu−Zn
complexes of molecular formula [(CuL)2Zn(dca)2] (1),
[(CuL)2Zn(NO3)2] (2), [(CuL)2Zn2(Cl)4] (3), and
[(CuL)2Zn2(NO2)4] (4) have been synthesized by reacting
[CuL] as a “metalloligand (ML)” (where HL = N,N′-bis(5-
chloro-2-hydroxybenzylidene)-2,2-dimethylpropane-1,3-diamine)
and by varying the anions or coligands using the same molar ratios
of the reactants. All of the four products including the ML have
been characterized by infrared and UV−vis spectroscopies and
elemental and single-crystal X-ray diffraction analyses. By varying
the anions, different structures and topologies are obtained which
we have tried to rationalize by means of thorough density
functional theory calculations. All of the complexes (1−4) have now been applied for several biological investigations to
verify their therapeutic worth. First, their cytotoxicity properties were assessed against HeLa human cervical carcinoma along
with the determination of IC50 values. The study was extended with extensive DNA and protein binding experiments followed
by detailed fluorescence quenching study with suitable reagents to comprehend the mechanistic pathway. From all of these
biological studies, it has been found that all of these heterometallic complexes show more than a few fold improvement of their
therapeutic values as compared to the similar homometallic ones probably because of the simultaneous synergic effect of copper
and zinc. Among all of the four heterometallic complexes, complex 3 exhibits highest binding constants and IC50 values suggest
for their better interaction toward the biological targets and hence have better clinical importance.
■ INTRODUCTION
Metal complexes can be classified as simple organic ligand-
bound metal centers forming a precise three-dimensional
arrangement. Therefore, synthesis of these transition-metal
complexes can be easily done in just fewer steps with greater
flexibility, attained by slight modification in each steps. Now,
the specially designed metal complexes bearing suitable donor
atoms can further be conveniently used as a “complex as a
ligand”1−3 for the synthesis of multinuclear heterometallic
complexes, one of the most attracted frameworks to structural
chemists since the last two decades. The ongoing interest on
heterometallic transition-metal complexes is principally owing
to their miscellaneous applications ranging from catalytic
activity,4 magnetic devices,5,6 and liquid crystalline materials7
to sensor design8 and finally, most importantly as therapeutic
drugs.9,10 The common research in heterometallic chemistry
majorly concentrates over molecular magnetism nurturing the
strategy of single-molecule magnets leaving the biomedical
application a less explored corner, although it may open up a
new avenue in drug development. Thus, in the present
perspective, we have therefore been motivated to develop
heterometallic complexes having a potential therapeutic
function. Although in the recent progress of medicinal
research, huge applications have already been done using a
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variety of homometallic complexes as metal-based therapeutic
agents,11−15 leaving the heterometallic systems an untouched
arena. To design the therapeutically active heterometallic
complex, the goal in our mind was that the inclusion of two
unlike cytotoxic metals in the same molecule would progress
their biomedical activity as the interaction of two different
metals with multiple biological targets may improve their
physicochemical properties with respect to the homometallic
one. Therefore, in this context, we have chosen to design
heteronuclear complexes particularly comprising copper and
zinc within the same ligand framework mainly because of this
three principal reasons: (i) due to their mimicking ability like
active site center in copper zinc superoxide dismutase.16,17 (ii)
Many copper-containing complexes have possible medicinal
value in curing various diseases including cancer.18,19 (iii)
Zinc-containing complexes can exhibit awfully good activity
toward the phosphate bond cleavage as it is in the active site
center of phosphatase, which may therefore be utilized as a
DNA-cleavage agent.20,21 Therefore, it has thought that their
combination may advance their therapeutic value based on
these abilities. In order to reach our goal, the ligand of our
choice in the present study is 2,2′-((1E,1′E)-((2,2-dimethyl-
propane-1,3-diyl)bis(azanylylidene))bis(methanylylidene))bis-
(4-chlorophenol), a tetradentate N,N,O,O donor ligand, and
first reacting it with copper(II) perchlorate, we obtained the
mononuclear copper complex which is further used as the
metalloligand (ML) to obtain the multinuclear heterometallic
complexes in the presence of zinc salts by varying the anions.
The four new heterometallic complexes (1, 2, 3, and 4) so
achieved illustrate anion-dependent structural variation which
has been methodically characterized by X-ray diffraction
studies, followed by thorough rationalization in terms of
density functional theory (DFT) calculations. Finally, the
heterometallic complexes have been applied to investigate their
mode of action toward various biological processes to see their
clinical importance. The detection abilities here include the
first cytotoxicity study using HeLa cancer cells22 with the
determination of IC50 values, suggesting that the compounds
present a higher cytotoxic activity because of the synergic effect
of both metal ions Cu and Zn than the similar homometallic
complexes. Next, we have done the DNA-binding experiments
with fish sperm DNA (FS-DNA), where complex 3 gives the
highest binding constants; this study was further extended by
fluorescence quenching with methylene blue (MB) to get more
insight on the intercalative mechanism. Finally, protein binding
studies have been executed to evaluate the complexes’
transporting ability as a drug using bovine serum albumin
(BSA) as a carrier protein. The protein interaction was
assessed by the tryptophan quenching study, and the
corresponding binding constant and numbers of binding sites
have been determined using complex 3 as the model. In
particular, all of these synthesis, characterization, theoretical
rationalization, and biological studies have been well
documented in this paper.
■ COMPUTATIONAL AND BIOLOGICAL DETAILS
Theoretical Methods. BP86/def2TZVP has been applied
to perform the calculations using the program TURBOMOLE
version 7.0.23 For reproducing the solvent effects, the
conductor-like screening model COSMO, a variant of the
dielectric continuum solvation models,24 has been employed.
Cytotoxicity Tests. Preparation of Solutions of Drugs. A
stock solution of the compounds at a concentration of 2 mM
was prepared in dimethyl sulfoxide (DMSO), subsequently;
the solution was diluted with water to various working
concentrations. It is important to note that in no case, the
quantity of DMSO in the solution was exceeding 0.5% to
assure this is nontoxic to treated cells. DMSO was used
because of the solubility problems. The nutrient medium was
the Dulbecco’s modified Eagle’s medium, with phenol red,
supplemented with L-glutamine (2 mM), streptomycin (100
μg/mL), and penicillin (100 U/mL), and 10% fetal bovine
serum. A Sodium 3′-[1-(phenylaminocarbonyl)-3,4-tetrazo-
lium]-bis(4-methoxy-6-nitro)-benzenesulfonic acid hydrate
(XTT) cell proliferation kit (Roche Molecular Biochemicals,
Mannheim, Germany) was prepared according to the
manufacturer’s instructions. All reagents were purchased
from Sigma Chemicals. For the normal cells, the CellTiter-
Glo 2.0 luminescent cell viability assay (Promega) was
prepared according to the manufacturer’s instructions.
Cell Culture. Human cervix adenocarcinoma HeLa cells
were cultured as monolayers in the nutrient medium. The cells
were grown at 37 °C in 5% CO2 and humidified air
atmosphere and were subsequently seeded (1500 cells per
well) into 96-well microtiter plates, and 24 h later, after the cell
adherence, different concentrations (10−5 to 10−9 M) of
investigated compounds were added to the wells. Only the
nutrient medium and DMSO were added to the cells in the
control wells. Human bone marrow stroma cells [HS-5
(ATCC CRL-11882)] and human lung fibroblasts [MRC-5
(ATCC CCL-171)] were cultured as monolayers in the
nutrient medium. The cells were grown at 37 °C in 5% CO2
and humidified air atmosphere and were subsequently seeded
(1500 cells per well) into 96-well microtiter plates, and 24 h
later, after the cell adherence, different concentrations (10−5 to
10−9 M) of investigated compounds were added to the wells.
Only the nutrient medium and DMSO were added to the cells
in the control wells. All experiments were done in triplicate.
Determination of Target Cell Survival. Seventy-two hours
after compound addition, cell survival was quantified using a
XTT cell proliferation kit (Roche Molecular Biochemicals,
Mannheim, Germany), following the instructions provided by
the manufacturer. A mixture solution of the labeling reagent
XTT and the electron-coupling reagent N-methylphenazinium-
methylsulfate was added to each well (50 μL of each). The
mixtures were incubated for 4 h in a humidified atmosphere
(37 °C, 5% CO2), and as a formazan product is generated, the
absorbance was measured with a microtiter plate reader at 450
nm using a reference wavelength of 630 nm. The IC50 (50%
inhibitory concentration) was calculated as the drug
concentration causing a 50% inhibition of cell proliferation.
For the normal cells 72 h after compound addition, cell
survival was quantified using a CellTiter-Glo 2.0 luminescent
cell viability assay (Promega), following the instruction of the
manufacturer. The reactive (50 μL) was added to each well,
and the plate was shaken for 10 s and incubated at room
temperature for 10 min. The luminescence was measured with
a VICTOR X3 multilabel plate reader, and as in the case of the
HeLa cells, the IC50 (50% inhibitory concentration) was
calculated as the drug concentration causing a 50% inhibition
of cell proliferation.
Binding Experiments. DNA-Binding. FS-DNA was
purchased from Sigma-Aldrich. The spectroscopic titration of
FS-DNA was carried out in a Tris-amine buffer prepared at
room temperature with the following composition 50 mM
NaCl−5 mM Tris-HCl and which has a pH of 7.4. A solution
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of FS-DNA in the buffer gave a ratio of UV absorbance 1.8−
1.9:1 at 260 and 280 nm, indicating that the DNA was
sufficiently free of protein.25 Nanopure water was used to
prepare the solutions, and the DNA concentration per
nucleotide was determined by UV−visible spectroscopy using
the known molar extinction coefficient value of 6600 M−1 cm−1
at 260 nm.26 Titrations were followed by absorption
spectroscopy at 260 nm using fixed complex concentrations
and adding increments of the DNA stock solution. Complex−
DNA adduct solutions were incubated at 37 °C for 30 min
before recording the absorption spectra.
BSA Interaction Studies. BSA was purchased from Sigma-
Aldrich. The interaction of the synthesized materials with BSA
was measured by absorption spectroscopy; the interaction
studies were carried out at room temperature using the buffer
with a composition of 50 mM NaCl−5 mM Tris-HCl and a
pH of 7.4. A solution of BSA in the buffer (using nanopure
water to prepare the solutions) was used, and all of the
spectroscopic studies were carried out between 200 and 500
nm by using a fixed concentration of complex and adding
different quantities of BSA solution. The adducts formed by
the metal complexes and BSA were incubated at 37 °C for 30
min before recording the UV−visible absorption spectra.
Tryptophan Quenching Experiment and Determination
of Binding Constant and Number of Binding Sites. BSA
fluorescence emission spectra have been recorded in the
presence of increasing concentrations of the studied complex
and in the absence of the studied complex to determine the
possible interaction between the studied Zn−Cu complex and
BSA. It is generally agreed that the BSA fluorescence is coming
from tryptophan (Trp), located on the surface of the domain,
Trp-213 located in the hydrophobic pocket of domain II, and
phenyl alanine (Phe) residues. In all cases, it is observed that
BSA solutions have the fluorescence emission at 345 nm upon
excitation at 285 nm.
■ RESULTS AND DISCUSSION
Synthesis, Rationalization, and Characterization of
the Metal Complexes. Four structurally characterized
heterometallic complexes have been synthesized using the
sequential procedure in which the methanolic solution of the
zinc salts as the second metal is added to the methanolic
solution of the ML [CuL] (Scheme 1). In some cases
(complexes 1 and 4), bridging salts (dca− and NO2
−) are
added to the heterometallic solution in order to obtain the
coordination polymers.
FT-IR and UV−Visible Spectra of the Complexes.
Fourier transform infrared spectroscopy (FT-IR) spectra of all
of the four heterometallic complexes and the ML are presented
in Figures S1−S5. The ML shows a CN stretching
frequency at 1623 cm−1 and skeletal vibration at 1533 cm−1.
For the heterometallic complexes, they all possess a band in
the region of 1634−1647 cm−1 because of the azomethane
(CN) group and show skeletal vibration around 1520 cm−1.
Complex 1 displays a sharp peak at 2150 cm−1 because of
coordinated dicyanamide anion, whereas complex 2 exhibits a
peak at 1379 cm−1, which is characteristic of nitrate. Complex
3 is a halide-containing species which therefore does not show
any characteristic sharp peak for anions. Complex 4 is a nitrite-
bridging species which hence displays a sharp peak at 1414
cm−1 characteristic of nitrite.
The absorption spectra of the complexes have been
performed in the DMSO medium at room temperature and
are shown in Figure S6. All of the complexes exhibit similar
absorption spectra with an intense band at around 375 nm very
similar to that of the ML, clearly indicating that here a ligand-
to-metal charge transfer occurs in the ML complexes which
persists also in the presence of the d10 metal ion zinc.
Crystal Structure Description of the Complexes.
Metalloligand. An ORTEP view of ML, used as the “ML”
building unit for the synthesis of polynuclear complexes here
described, is reported in Figure 1. A selection of bond lengths
and angles is reported in Table S1. In the complex, the CuII ion
Scheme 1. Formation of Complexes 1−4
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is coordinated in a slightly distorted square-planar environ-
ment by the N and O atoms of the tetradentate ligand. The
complex atoms with the exception of the propyl chain are
practically coplanar, and the dihedral angle between the
salicylaldimine moieties is of 7.22°. The Cu−O and Cu−N
bond distances are within the normal ranges being of 1.905(2)
and 1.903(2) Å and of 1.947(3) and 1.953(3) Å, respectively.
The crystal packing shows complexes piled along axis a
alternatively in the head−tail fashion related to the center of
symmetry. This arrangement allows the phenyl rings to be
faced showing π−π interactions (centroid-to-centroid dis-
tances of 3.828(2) and 3.838(2) Å).
Complexes 1 and 2 are trinuclear species in which two CuL
(ML) units bridge central Zn atom in a centrosymmetrical
fashion, where the copper and zinc ions exhibit a square
pyramidal and octahedral coordination geometry, respectively.
A perspective view of the polymeric unit of complex 1 and that
of complex 2 are shown in Figures 2 and 4, respectively.
An ORTEP view of complex 1 is shown in Figure 2. Here, a
pair of μ1,5-dicyanoamide anions bridges the zinc and copper
ions of trinuclear units, thus forming a polymeric chain along
crystallographic axis c, as depicted in Figure 2. The
dicyanoamide has been used in trinuclear Cu−M−Cu similar
complexes (M = Co, Ni, and Zn), obtaining a 2D polymeric
network instead.27 Complex 1 shows the basal Cu−N and
Cu−O bond distances following a trend similar to other
complexes, whereas the apical Cu−N(dca) is of 2.479(5) Å.
The Zn−O bond lengths, with a mean value of 2.180 Å, are ca.
0.1 longer than those measured in complex 2, but Zn−N(dca)
is of 2.031(4) Å. Thus, the μ1,5-dca connector exhibits an
asymmetric coordination, which is more strongly bound to Zn.
The intermetallic Cu−Zn distance within the trinuclear entity
is of 3.1891(8) Å, and the dca spaces the metals along the
chain at 8.9152(13) Å (Figure 3).
In the discrete complex 2, the metals are bridged by two
nitrate anion symmetry related to the center of inversion
(Figure 4). Each anion is disordered over two positions at half
occupancy in order to avoid, for one of these steric clashes with
a lattice water molecule O1w (occupancy 0.5). In the square
pyramidal coordination geometry of copper, the basal Cu−O
and Cu−N bond lengths are comparable to those detected in
other compounds reported here. On the other hand, the apical
position is occupied by disordered nitrate oxygens O(3) and
O(3b) at 2.356(11) and 2.323(12) Å, respectively (Figure S7),
considerably shorter than the Cu−O(nitrite) value measured
in 4 (of 2.593(3) Å).
On the other hand, in the octahedral ZnO6 chromophore,
the Zn−O bond distances are in the range 2.045(3)−
2.084(10) Å, but the distance involving oxygen O(4b), of
the second nitrate fragment, is significantly longer (2.279(11)
Å). The intermetallic Cu−Zn distance is of 3.0178(6) Å.
Figure 1. ORTEP drawing (ellipsoids at 50% probability) of ML.
Figure 2. ORTEP drawing (ellipsoids at 35% probability) of the
centrosymmetric unit of polymeric complex 1 (inset: coordination
environment around CuII and ZnII centers).
Figure 3. Polymeric structure of complex 4 developed along
crystallographic axis c.
Figure 4. ORTEP drawing (ellipsoids at 35% probability) of
centrosymmetric trinuclear complex 2 of the disordered bridging
nitrate anion, only one fragment is shown (inset: coordination
environment around CuII and ZnII centers).
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Three such linear Cu−Zn−Cu complexes containing
bridging nitrate,28 acetate,29 and azide30 with salicylidene-1,3-
propanediaminate have been reported, showing that a Cu−Zn
distance is of 3.0017(6) Å.
Different from what observed in the tetranuclear complexes
where the phenol moieties of the ligand L are slightly tilted to
each other here is worth noting the umbrella shape
arrangement assumed by the symmetry related ligands L in
order to allow the formation of the trinuclear Cu−Zn−Cu
derivatives. This conformation (Figure 5) is such that the
phenol rings form close comparable dihedral angles of 57.93°
and 59.98°, in complexes 1 and 2, respectively.
By using anions chloride or nitrite, we obtained tetranuclear
Cu2Zn2 complexes, [CuLZnCl2]2 (3) and [CuLZn(NO2)2]2
(4). Both are structurally related and can be considered as a
dimmer of two diphenoxo-bridged dinuclear CuLZn moieties
connected by bridging Cl− or NO2
− anions in a centrosym-
metric fashion, crystallizing in the monoclinic space group P21/
c. An ORTEP diagram of the two complexes is shown in
Figures 6 and 7, and the bond lengths and angles of the
coordination sphere are listed in Tables S5 and S6,
respectively.
In complex 3, which as-mentioned above is closely related to
4, the geometry around copper is still in a distorted square
pyramidal geometry with a τ parameter of 0.118. Here, the
Cu−N and Cu−O bond lengths are of 1.975(3) and 1.935(4)
and 1.929(3) and 1.939(3) Å, respectively. The apical position
is occupied by chloride at considerably long distance Cu−
Cl(4′), 2.8484(15) Å, that however does not exclude an
interaction between these atoms. On the other hand, the zinc
ion possesses a distorted tetrahedral coordination sphere built
by the phenolate oxygens (Zn−O distances of 1.990(3) and
1.999(3) Å) and two chlorides (Zn−Cl of 2.1929(12) and
2.2057(12) Å). The coordination angles about Zn are in the
range 110.56(10)−120.12(10)° with the exception of O(1)−
Zn−O(2) of 76.56(11)°. The salicylaldimine moieties are
tilted to form a dihedral angle of 23.30°.
In complex 4, the geometry around copper can be best
described as a distorted square pyramidal geometry as
indicated by the τ parameter value of 0.125 (τ = 0 and 1 for
a perfect square-pyramidal and trigonal bipyramidal geometry,
respectively).31 The basal plane of the five-coordinated Cu ion
consists of two amine nitrogen atoms (Cu−N bond distances
of 1.937(3) and 1.979(3) Å) and two phenolic oxygens (Cu−
O bond distances 1.951(2) and 1.925(2) Å), whereas the
apical position is occupied by a bridging nitrite oxygen atom
(Cu−O(3′) of 2.593(3) Å). The two salicylaldimine moieties
are tilted about the central copper atom, forming a dihedral
angle of 23.95°. The zinc ion exhibits a distorted octahedral
geometry in an O6 donor set realized by two bridging nitrite
anions and by the phenolate oxygen atoms. The Zn−
O(phenol) distances are 2.030(2) and 2.018(2) Å, whereas
Zn−O(nitrite) is significantly longer in between 2.143(3) and
2.223(3) Å. The deviations from the ideal octahedral geometry
are clearly demonstrated by the coordination bond angles
reported in Table S5; these vary from ca. 57° for the bridging
anions to 147.75(11)°.
It is worth noting the similarity in the arrangement of the
metal atoms in the tetranuclear core (Figure 8). In fact, the
Cu−Zn and Cu−Zn′ intermetallic distances are 3.0709(5) and
Figure 5. View along the Cu−Cu′ direction in the trinuclear
complexes 2 and 1, showing the conformational arrangement assumed
by the two L ligands.
Figure 6. ORTEP drawing (ellipsoids at 40% probability) of
centrosymmetric tetranuclear complex 3 (inset: coordination environ-
ment around CuII and ZnII centers).
Figure 7. ORTEP drawing (ellipsoids at 40% probability) of
centrosymmetric tetranuclear complex 4 (inset: coordination environ-
ment around CuII and ZnII centers).
Figure 8. Arrangement of metal atoms in the tetranuclear core of
complexes 3 and 4.
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4.7024(5) Å, respectively, in complex 4, to be compared with
the corresponding figures in 3 of 3.0526(8) and 4.6117(8) Å,
respectively.
Solution Studies: Mass Spectrometry. In order to
determine the compositions of heteronuclear complexes
essential to understand their solution chemistry, we have
performed the mass spectral study in the DMSO−acetonitrile
mixture. All of the mass spectra are given in the Supporting
Information (Figures S9−S12). Complex 1 dissociates into
two species with a base peak of 1063.0159 amu ([CuL2Zn-
(dca)(H2O)]
+, calcd 1063.9759 amu) and a small peak arising
at 1015.0287 amu (calcd 1091.9767 amu) responsible for the
monocation [CuL2Zn(H2O)2]
+. Complex 2 on the other hand
displays only one peak, i.e., the base peak arising at 1043.6355
amu for the formation of the monocation [CuL2Zn(NO2)-
(H2O)]
+. These species ought to be formed because of the
stepwise ionization of the coligands dicyanamide for the first
one and nitrate for the latter. Complexes 3 and 4 dissociate
into dinuclear heterocomplexes as evident from their mass
spectra, the base peaks appear at 555.0591 amu (calcd
555.9127 amu) and 566.1590 amu (calcd 566.9367 amu),
respectively. In the case of 3 and 4, two hetero-dinuclear
moieties are coordinated by weak chloro or nitrito interaction,
which disrupts upon solvation to produce the monopositive
hetero-dinuclear species.
Theoretical Rationalization of Anion-Dependent Struc-
tural Variation. Experimentally, the nuclearity of the
complexes formed by the ML CuL depends on the nature of
the counter anion (see Figure S8). That is, compound 1 is a
trinuclear dca (dicyanamide)-bridged polymer, compound 2
(NO3
−) is a trinuclear (Cu2Zn) monomeric complex, and
compounds 3 (Cl−) and 4 (NO2
−) are tetranuclear (Cu2Zn2)
monomeric complexes. The present DFT study is intended to
give some insights into the different nuclearities observed in
these complexes. We have focused our analysis to compounds
2−4 because the polymeric nature of 1 can be simply
rationalized by considering the intrinsic linear geometry of the
dicyanamide ligand. For this study, we have fully optimized in
MeOH compounds 2−4 and also the hypothetical tetranuclear
complex 2′ (Figure 9d) and trinuclear complexes 3′ and 4′
(Figure 9b,c). The geometric features of the optimized
complexes (given in Figure 9) are in good agreement with
the X-ray geometries, giving reliability to the level of theory
used herein. In Figure 9, we also include the energetic results
for the hypothetical transformation of the trinuclear complexes
to the tetranuclear ones by the reaction with the appropriate
Zn(II) salt. The transformation of the trinuclear complex into
the tetranuclear one is energetically favorable in all cases.
However, in the solid state, the tetranuclear complex is only
observed for Cl− and NO2
− anions (compounds 3 and 4).
Therefore, this DFT preliminary analysis is not able to explain
the formation of the trinuclear complex 2. Moreover,
stoichiometrically, the CuL/Zn proportion used (2:1) is
adequate for the formation of the trinuclear assembly.
Therefore, the formation of the tetranuclear complexes in 3
and 4 implies that a significant proportion of ML has not
reacted.
In general, the rationalization of the nuclearity is
complicated because in the solid state, the packing forces
and noncovalent interactions with the neighbor molecules are
crucial in determining the final solid-state architecture.
Therefore, the most-favored nuclearity in the solid state can
be different than that in the solution state. The main difference
between compounds 2 (trinuclear) and 4 (tetranuclear) is
simply the presence of an additional O atom in the anion
(nitrate vs nitrite). This uncoordinated O atom in 2 is pointing
to the external part of the complex, perfectly suited for
establishing intermolecular interactions. We have analyzed this
issue by examining the crystal packing of 2. We have found
that each NO3
− anion in 2 establishes an H-bonding
interaction with the adjacent molecule. We have computed
the interaction energy of the assembly shown in Figure 9
(using the crystallographic coordinates), which is ΔE4 = −29.8
kcal/mol. Interestingly, this interaction energy is able to
compensate the −21.9 kcal/mol difference between the
trinuclear and tetranuclear complexes in MeOH. Keeping in
mind the complexity of the intricate combination of forces
present in the solid state, we propose that the formation of
Figure 9. Optimized geometries of compounds 2−4 (a,e,f, respectively) and their hypothetical complexes 2′−4′ (d,b,c, respectively). Distances in
Å.
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compound 2 (trinuclear) is due to the formation of additional
interactions in the solid state that are able to compensate the
energetic difference with the tetranuclear one. However,
compounds 3 and 4 crystallize in their most stable solution
form, indicating that the additional interactions of their
hypothetical trinuclear complexes are not able to compensate
the energetic differences shown in Figure 9.
Biological Studies. The cytotoxic effect of the investigated
metal complexes was examined against HeLa cancer cell lines
using the XTT assay; IC50 values are summarized in Table 1. It
is clearly seen that all of the compounds 1−4 are cytotoxic to
the studied cell with IC50 values very close to 1 μM. From all of
these compounds and considering the standard deviation, the
most active complex was 3 with 2 and 4 being very close in
cytotoxicity. It seems that the structural similarities of the
compounds are correlated with very uniform cytotoxic
activities.
In general, the compounds reported here showed a much
higher cytotoxicity than other reported zinc or copper
compounds with similar ligands which were found in the
literature to be up to two magnitude orders less cytotoxic than
1−4.32−34 It seems that the compounds present a higher
cytotoxic activity because of the synergic effect of both metal
ions Cu and Zn.
However, we have also carried out the study of the toxicity
of 1−4 against normal cells (human bone marrow stroma cells
HS-5 and human lung fibroblasts MRC-5); unfortunately, the
compounds do not show selectivity against cancer cells on
direct comparison with HS-5 or MRC-5. This is maybe due to
the mechanism of cytotoxication of the compounds which is
likely based on the generation of reactive nitrogen species
(RNS) or reactive oxygen species (ROS) because of the NO-
containing ligands of compounds 1−4.35,36 In this context,
normal cells are usually more sensitive to RNS or ROS;
therefore, future studies of our research groups will be focused
on the design of novel heterometallic compounds including
recognizable fragments (such as folates or similar) whose
receptors are usually over-expressed in cancer cells. In this
context, we think that the compounds may be selective toward
cancer cell lines and improve their applicability in future
chemotherapeutic treatments (Figure 10).
DNA Interaction Study. The determination of the binding
properties of metal complexes with molecules of biological
interest can be carried out by a study of the evaluation of the
interactions of metallodrugs with DNA by UV−visible
absorption spectroscopy. Binding to biomacromolecules is
usually associated with modifications of the electronic
spectrum of both the compounds, which is interacting or the
biomolecule.37 It is generally agreed that hypochromism and
bathochromism effects mean an intercalation of the metal-
lodrug to DNA associated with strong (π → π*) stacking
interactions between aromatic chromophores of the studied
binding complex and DNA base pairs.38,39 Additionally, the
hyperchromism effect is usually associated with the interaction
of the metal complex with the minor groove of DNA, meaning
an unwinding of the DNA double helix leading to unstack and
exposure of the nitrogen bases of the DNA chain.40,41 As an
example, Figure 11 shows the electronic absorption spectra of
3 (one of the most active compounds of the present series) in
the absence and presence of FS-DNA.
In our study, we have observed that the addition of
increasing amounts of DNA to the studied compounds 1−4
leads to hyperchromism (increase of absorption intensity) in
the UV−visible absorption spectrum which is a consequence of
the minor groove binding of complexes 1−4 to DNA and the
unwinding of the DNA double helix. In addition, we observed
a slight blue shift in the absorption maximum which confirms
the possibility of an electrostatic interaction between the
studied compounds 1−4 and the DNA chain.
In order to compare the binding strengths of the complexes,
the intrinsic binding constant, Kb, was determined using the
following eq 1.42
K
DNA DNA 1
( )a f b f b b fε ε ε ε ε ε
[ ]
−
= [ ]
−
+
− (1)
Table 1. IC50 (μM ± SD) of the Studied Compounds (1−4)
against HeLa Cancer Cells, HS-5 and MRC-5 Fibroblasts
complex
IC50 (μM ± SD) in
HeLa cells
IC50 (μM ± SD) in
HS-5 cells
IC50 (μM ± SD) in
MRC-5 cells
1 1.010 ± 0.020 0.120 ± 0.010 0.135 ± 0.005
2 0.967 ± 0.017 0.105 ± 0.005 0.115 ± 0.005
3 0.973 ± 0.073 0.105 ± 0.005 0.120 ± 0.010
4 0.975 ± 0.025 0.094 ± 0.006 0.110 ± 0.010
Figure 10. Detail of the H-bonding interaction involving the nitrato
ligand in compound 2 and the interaction energy of the assembly.
Distance in Å.
Figure 11. Electronic spectra of complex 3 in a buffer solution (5 mM
Tris-HCl/50 mM NaCl at pH 7.4) without and with the addition of
different concentrations of FS-DNA. C(complex) = 1.5 × 10−5 mol
L−1 and C(DNA) = 0−5 × 10−5 mol L−1. Arrow shows that the
absorption intensities increase upon increasing the DNA concen-
tration. Inset: Plot of [DNA]/[εa − εf] vs [DNA] for the titration of
complex 3 with DNA.
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where [DNA] is the concentration of DNA in base pairs, εa, εf,
and εb correspond to Aobs/[complex], the extinction coefficient
of the free complexes, and the extinction coefficient of the
complexes in the fully bound form, respectively, and Kb is the
intrinsic binding constant. The ratio of slope to intercept in the
plot of [DNA]/(εa − εf) versus [DNA] gives the value of Kb
(inset Figure 11).
Using this method, the intrinsic binding constants of
compounds 1−4 were, respectively, of 3.61 × 104, 2.92 ×
104, 4.24 × 104, and 2.88 × 104 M−1, observing that they are all
in the same order of magnitude. The highest binding constant
is found for compound 3 which again, as in the case of the
study of the cytotoxic activity, seems to have a slightly higher
binding ability to DNA.
Fluorescence MB Experiments. Additional fluorescence
experiments were carried out to get more insights on the
mechanism of interaction of complex 3. Thus, a competitive
measurement in the presence of the typical intercalator MB
was carried out. It is well known that MB is a planar molecule
that has usually been utilized for dying in different specific
biological assays.43 MB usually inserts into each of the DNA
strands because of its positive charge which can electrostati-
cally interact with DNA anions giving intercalating bonds
which are irreversible. This makes that the emission and
absorption spectra of the MB adducts highly depend on the
type of the bond.44,45
Thus, a fluorescence method was carried out to investigate
the interaction of complex 3 with an adduct DNA−MB
([DNA]/[MB] = 10) using increasing concentrations of the
metallodrug. After the addition of 3, the emission intensities of
the adducts were recorded, observing that the addition of 3
seems to quench the MB emission intensity, so that the
emission spectra of MB-DNA solutions decreased considerably
in the presence of increasing amounts of 3 (Figure 12). This is
an indication of a possible insertion of the complex into the
DNA double helix, which is associated with an intercalative
binding behavior as observed in the previous studies using UV
spectroscopy.
Protein Binding Studies. Interactions with BSA Deter-
mined by Absorption UV-Spectroscopy. Albumin is a very
important transport protein which is usually contributing to
the transport of some external agents to the interior of the
cells. Thus, structural changes in the mechanism of complex
formation in the donor−acceptor system characteristic of
metallodrug interactions with different proteins such as
albumin can be studied by UV−visible absorption spectrosco-
py. This method is very effective to determine changes in the
absorption bands to determine and understand the interactions
of metal complexes with proteins.46 The absorption spectrum
of BSA has two simple bands at 220 and 280 nm because of the
absorption peak of BSA polypeptide structure and the different
aromatic amino acids which can be found in the protein
structure (tryptophan, tyrosine, and phenylalanine). In this
context, as the transport of the metallodrug might be one of
the processes for a hypothetical cell internalization of the
complex, the interaction between 3 and the transport protein
albumin was determined on the basis of the UV−visible
absorption spectra.
The structural changes in BSA are usually indicated by
variations in the absorption band between 220 and 240 nm; in
addition, changes at 280 nm are usually induced by changes in
the sub-environments around BSA amino acids. For complex 3,
the BSA absorption intensity significantly decreased and in
some cases almost disappears in the range of 220−240 nm
upon addition of increasing amounts of the metallodrug
(Figure 13). As a consequence of the changes in the protein
structure, it is possible to observe a softer change on the
maximum absorption at 280 nm, which is indicating clear
structural changes with the α-helix of the primary substructure
of the protein which is probably a consequence of a specific
interaction between 3 and BSA.47 These results indicated a
high interaction of 3 with albumin, confirming that this
transport protein may be one of the possible biological targets
inducing the transport of this complex inside cells.
BSA Tryptophan Quenching. BSA fluorescence is generally
due to tryptophan (Trp) of BSA located on the surface of
domain, Trp-213 of the hydrophobic pocket of domain II, and
phenyl alanine (Phe) residues. Usually, solutions of BSA
present a fluorescence emission at 345 nm which is due to
Figure 12. Fluorescence emission spectra for MB-DNA adducts in
Tris-buffer in the absence and presence of increasing concentrations
of 3.
Figure 13. UV−visible absorption spectra for BSA in Tris-buffer in
the absence and presence of increasing concentrations of 3.
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tryptophan residues, upon excitation at 285 nm. The
fluorescence intensity of the peak 345 nm decreased upon
increasing concentrations of metal complex which confirms the
conformational changes in the secondary structure of the
protein due to interaction with complex 3 which quenches its
intrinsic fluorescence. The quenching mechanism between
complex 3 and BSA is described by the linear Stern−Volmer
equation (eq 2).
F
F
K K1 Q 1 Q0 sv q 0τ= + [ ] = + [ ] (2)
where F0 and F are BSA fluorescence intensities in the absence
and presence of metal complex, respectively, and Kq, Ksv, τ0,
and [Q] are the BSA quenching rate constant, the dynamic
quenching constant, the average BSA lifetime in the absence of
quencher (estimated in 10−8 s−1) and the quencher
concentration, respectively.
Using this method, we were able to determine Ksv for
complex 3 which was 1.02 × 1012 M−1 s−1 which is in the range
for other metal-based drugs.48 These results are in agreement
with a static quenching interaction as reported previously for
similar compounds.48
Determination of Binding Constant BSA-3 and the
Number of Binding Sites. For the determination of the
binding constant (Ka) and the number of binding sites (n) for
the static quenching interaction, assuming similar and
independent binding sites in the biomolecule, the following
equation (eq 3) is governing the fluorescence emission
F F
F
K nlog
( )
log log Q0 a
− = + [ ]
(3)
where n is the average number of binding sites per albumin
molecule and Ka is the binding constant in the protein complex
interaction. For the system complex 3BSA, Ka and n values
at room temperature were 3.31 × 103 M−1 and 0.78,
respectively. These results show that complex 3 has a moderate
binding constant44 and that 3 is implied in only a single
binding site in each albumin.
■ CONCLUSIONS
The applications of heterometallic compounds are majorly
being concentrated over the branch of magnetism. Numerous
researchers are busy cultivating the magnetic properties in
order to develop SMM and other magnetic devices, becoming
the route over-saturated while leaving the biomedical
applications untouched. This furnishes us the sufficient
opportunity to investigate the clinical values of these
heterometallic systems by employing them in different
biological tests as therapeutic drugs. In order to carry out
the job, we have taken two different biorelevant transition
metals copper and zinc to incorporate in a single framework.
Four different heterometallic complexes were obtained from
these systems by varying the corresponding coligands.
Strikingly, all of them have found to show high biomedical
properties. The complexes demonstrate moderate cytotoxicity
against HeLa cancer cells as evidenced by the XTT assay. Also,
they provide high DNA binding capability through inter-
calative mechanism, and finally, they can be successfully
transported as a drug to cells as verified by the BSA protein
transport mechanism. In the latter two cases, fluorescence
quenching studies have been carried out to get insight into the
detailed mechanistic pathways. All of these experimental results
show that the heterometallic complexes exhibit high
cytotoxicity and binding constants and their values are quite
a fold increase with respect to similar homometallic complexes.
Finally, from this study, we are able to conclude that
heterometallic complexes have better biomedical values and
can be constructed as therapeutic drugs, advancement of their
clinical properties possibly owing to the better interaction
(synergic effect) of different metals with a single biological
target.
■ EXPERIMENTAL DETAILS
Physical Methods and Materials. 5-Chloro salicylalde-
hyde and N,N-dimethylethylenediamine were purchased from
Sigma-Aldrich. Reagent-graded organic reagents and solvents
are used for synthesis required during this entire project. They
were purchased from marketable resources and further distilled
before use. Milli-Q graded water had been used in all physical
measurements and experiments. Elemental analyses (carbon,
hydrogen, and nitrogen) were performed by a PerkinElmer
240C analyzer, and for recording infrared spectra, Shimadzu
FTIR-8400S and PerkinElmer Spectrum Express Version 1.03
were used (4000−400 cm−1) at 28 °C using KBr pellets as
mediums. The observation of the UV−visible spectra was
carried out by a Shimadzu UV-2450PC spectrophotometer
equipped with multiple cell-holders and thermostat.
The preparation and composition using the stepwise
technique are discussed elaborately in the Supporting
Information
X-ray Data Collection and Structure Determination. A
Bruker Smart Apex diffractometer (Mo Kα radiation, λ =
0.71073 Å) equipped with a charge-coupled device was utilized
to collect the intensity data for crystal structure analyses of ML
and all of the compounds 1−4 at room temperature. For cell
refinement, indexing, and scaling of the data sets, the program
Bruker Smart Apex and Bruker Saint packages49 were used. All
structures were solved by direct methods and subsequent
Fourier analyses50 and refined by the full-matrix least-squares
method based on F2 with all observed reflections.50 Bridging
nitrate anion in compound 2 was found disordered on two
positions, refined at half occupancy with isotropic thermal
ellipsoids. In addition, in complex 2, the ΔF map revealed the
presence of a residual interpreted as oxygen water at half
occupancy. All hydrogen atoms were placed at calculated
positions and included in final cycles of refinement. H atoms of
the water molecule in 2 at half occupancy were not located.
WinGX System, Ver 2013.351 was employed to perform all of
the required calculations. Crystal data and details of refine-
ments are given in Table S1.
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